Freenome just published pivotal trial results for its blood-based colorectal cancer (CRC) screening test in JAMA. With 79.2% sensitivity for CRC and 91.5% specificity, the test hit its primary endpoint—but struggled with precancerous lesions, showing just 12.5% sensitivity for advanced adenomas. That’s well below Exact Sciences’ 43% with Cologuard Plus.
While Freenome eyes FDA approval in 2025, the real battle may hinge on the U.S. Preventive Services Task Force’s judgment—and whether better versions can boost detection before cancer starts.